

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Senior Editor:** Ulrike Knies-Bamforth**Acting Senior Editor:** Sian Bithell**Content Development Manager:** Jacky Smith**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)20 7424 4314

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Mellior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica, China***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA***Janice Reichert** *Tufts Center for the Study of Drug Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

731 Open-source science to enable drug discovery*Aled Edwards*

CORRIGENDUM

824 Corrigendum to "Targeting mammalian target of rapamycin (mTOR) for health and diseases"*X.F.S. Zheng*

MONITOR

825 The major gut symbiont reduces its genome when it lives *in vitro**Vadim V. Demidov***827 Targeted library design for the generation of actives against biological targets
Peptidomimetic inhibitors of myeloid differentiation factor 88***Paul Edwards***829 DIARY****FORTHCOMING ARTICLES:****Limitations and Lessons in the Use of X-Ray Structural Information in Drug Design***By Andrew M Davis, Stephen A. St-Gallay and Gerard J Kleywegt***Chemically modified siRNA: tools and applications***By Jonathan K. Watts, Glen F. Deleavey and Masad J. Damha***Drug Discovery in the Era of Facebook - New Tools for Scientific Networking***By David S. Bailey and Edward D. Zanders***The public road to high quality curated biological pathways***By Michiel E. Adriaens, Magali Jaillard, Andra Waagmeester, Susan L.M. Coort, Alex R. Pico and Chris T.A. Evelo*